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INTRODUCTION
Anemia is a common hematological manifestation of
HIV infection associated with mortality especially
among those with advanced disease.1 Studies that
estimate the prevalence of anemia among HIV infected
persons in resource limited nations that bear the
greatest burden of the disease indicate that it ranges
from 40% to 90%.2 Several factors including stage of
HIV, age, sex, ART regimen, cut off  value for the
definition of anemia, and geographical location
contribute to the variation in rates of anaemia.2
Zidovudine (AZT), a thymidine nucleoside analog
reverse transcriptase inhibitor (NRTI), is effective in
the management of HIV infection. The projected
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market share of AZT for adults as a proportion of
NRTI stood at 20% as of 2016 in most low and middle
income countries.3 The WHO recommends use of
tenofovir (TDF) as a component of first-line ART
instead of AZT given the associated increased risk of
anemia.4 AZT-induced anaemia often occurs soon after
initiating treatment and this haematologic toxicity is
thought to be dose-dependent. Further, AZT-induced
anemia has been shown to increase the risk of mortality
and morbidity and adversely affect quality of life of
HIV-infected persons.5  Studies have established an
association between anemia at baseline and decreased
survival/increased disease progression in patients with
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Background: Zidovudine (AZT) is a common component of antiretroviral therapy
(ART) in resource-limited settings.   However, AZT is associated with myelotoxity
that often presents with anaemia. The aim of  this study was to determine the incidence
of  anaemia among patients initiated on AZT-containing and non-AZT containing
ART regimens.
Methods: In this retrospective analysis, records from 800 ART-naïve HIV-infected
patients  were abstracted by simple random sampling from program databases.
Rates of  anaemia were compared between patients initiated on AZT- versus non-
AZT-containing ART regimens. Patients were stratified according to absence (Group
A) or presence (Group B) of baseline anaemia defined as haemoglobin < 10.5g/dl.
Incidence was calculated as total cases of  AZT-induced anaemia (group A) or
worsening of anaemia (group B) during the study period divided by person-time at
risk and adjusted per 100 person-years. Average time-to-event and survival curve
were estimated using Kaplan Meier survival analysis.
Results: In group A (without baseline anaemia), the incidence of anaemia in the
AZT-exposed versus non-exposed cohorts was 73.3 and 17.6 per 100 patient years at
6 months, and 60.5 and 8.5 per 100 patient years at 12 months, respectively. In group
B, the incidence of worsening anaemia was 65.9 and 26.2 per 100 patient years at 6
months, and 57.5 and 17.9 per 100 patient years after 12 months in AZT-exposed and
AZT-unexposed cohorts, respectively. The estimated time to event (developing
anaemia) was 2.3 (1.5 – 3.4) months, while estimated to event (worseninig anaemia)
was 2.0 (1.5 – 4.0).
Conclusions: HIV-infected patients initiated on AZT-containing ART are 2.7 and
4.5 more likely to develop anaemia at 6 and 12 months, respectively, compared to
those initiating a non-AZT containing regimen. When censored at 12 months the
overall incidence of  AZT-related anaemia was estimated at 22.3% (38.2 incidences
per person years). Majority (75%) of  the AZT-related anaemia occurred early with
estimated time-to-event occurring within the first 3.8 months
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HIV.3-5. AZT-induced anaemia could result from bone
marrow depression, described as proliferative inhibition
of red cell progenitors6 or reversible pure red cell
aplasia (PRCA).7 In the Development of Antiretroviral
Therapy in Africa (DART) study in Uganda, it was
observed that 20% of  patients developed new anaemia
after initiation of  AZT-containing ART, with 5%
developing severe anaemia (hemoglobin level <6.5 g/
dL); 20% of the anaemia was classified as macrocytic
and thus presumably AZT-related.8 Yet most of  the
studies that evaluated AZT-induced anaemia were
conducted in Western countries and may not reflect
findings from developing nations. There is a dearth
of research from sub-Saharan Africa that has the
highest burden of  HIV infection. To the best of  our
knowledge, there are scarce published studies on AZT-
induced anaemia in Nigeria, particularly the north-
eastern part of  the country. We therefore evaluated
the incidence of  anaemia among HIV-infected patients
treated with AZT-containing ART in northeastern
Nigeria.
METHODS
This retrospective study was conducted at the University
of  Maiduguri Teaching Hospital (UMTH).  Participants
included HIV-infected adults and adolescents who were
initiated on ART from 2nd January 2010 to 30th
December 2011. The UMTH is a 530-bed hospital,
designated Centre of Excellence for Infectious
Diseases, that provides tertiary health care services to
individuals in north-eastern Nigeria and the neighboring
countries of  Cameroun, Chad, and Niger Republics.
Inclusion criteria
• Non-pregnant HIV-infected adults and
adolescents (i.e. >15 years old).
• Commenced ART for the first time in his/her life
within the period of  study at UMTH (i.e. ART-
naïve at commencement).




• Patients <15 years of age
• Subjects without any follow-up data
Eligible population for this study, considering the above
inclusion and exclusion criteria, was 1910 patients.
Censoring
Censoring of subjects during the study period was
determined by the following criteria:
• Development of anaemia during the study
• Switch of antiretroviral therapy
• Death
• Lost-to-follow-up
• End of the research
Sample size
Sample size was estimated using the formula:
 (Ibrahim, 2009)[9]
Where:
n= desired sample size for each of the cohort group
in an infinite sampling frame
= normal standard deviate (at 0.05 a-level, the
corresponding value of z is 1.96)
= normal standard deviate (at 80% power, the
corresponding value of z is 0.84)
p= Incidence of  AZT-induced anaemia, considered
15% (0.15) based on literature review
d= expected difference (0.05 would be considered at
95% CI)
n=  = 399.8
Thus, a sample size of 400 patients was required for
each group, including those receiving AZT-containing
and non-AZT containing regimens, in order to achieve
80% power with an alpha of 0.05. A total of 800
patient records were therefore required to study the
population.
Sampling techniques
Random sampling of electronic medical records was
employed to select the necessary sample size for each
group from their respective sampling frame. After
using both the inclusion and exclusion criteria to filter
the adult and adolescent databases, the final eligible
subjects were divided into two groups based on their
initial ART regimen (AZT-containing ART (1003) and
non-AZT containing ART (907)). Each group was
serially arranged and assigned sequential numbers. A
total of eight hundred (800) subjects (i.e. 400 subjects
from each of the group) were randomly selected using
the random number generator component of
Statistical Package for Social Sciences (SPSS) version
20.0). This process of sampling is explained by the
flow diagram below:
                                                    Annals of Ibadan Postgraduate Medicine. Vol. 16 No. 2, December 2018 117
Not assessed for eligibility (Total = 3771)
Patients who do not commence ART in 2010 & 2011,
n = 3201
 PMTCT patients  N =  570
Adults and adolescents on ART
N = 6001
Assessed for eligibility
Non- pregnant adults and adolescents
(ART-naïve in 2010 and 2011) N = 2230
Total eligible = 1910
Non-pregnant adults and adolescents with
both baselines lab. Values and follow-up lab.
Values
Excluded (Total = 320)
 Patients without baseline laboratory value n
=201
 Patients with baseline lab. Values without at least
single follow-up lab values n = 119
Sampled Size 800 patients
Figure 1: Flow diagram of patient selection
Fig.1: Flow diagram of  the cohort enrolled
Data collection:
Information abstracted from the database includes age,
gender, weight, haemoglobin concentration, CD4 cell
count and HIV viral load. Other information includes
use of co-trimoxazole as prophylaxis and ART
regimen.
Operational Definitions
Anaemia-of-all-causes: defined as a haemoglobin
concentration less than or equal to 10.5 gm/dl for
both male and female.
AZT-related anaemia: defined as all cases of
reported AZT toxicity that were documented in either
toxicity database or on the comment section of the
pharmacy database for subjects enrolled for the study.
Worsening anaemia: defined in this context as
reduction in haemoglobin concentration by greater than
or equal 1 gm/dl for subjects with baseline anaemia
Severe anaemia: defined using WHO anaemia
grading as a haemoglobin concentration less than 6.5
g/dl.
Thrombocytopenia: defined as platelet count of less
than 150,000/ìL.
Neutropenia: defined as absolute neutrophil count
(ANC) of less than1000cell/ml.
Renal impairment:  Defined as estimated creatinine
clearance (CrCl) less than 60 ml/min. The CrCl was
estimated using Cockcroft-Gault formula: for male
and multiplied by 85% for
female. The serum creatinine was in µmol/l.
Lost-to-follow: Defined as subjects with less than
six months follow-up data available.
Time-to-event (anaemia or worsening of anaemia):
Defined as the midpoint of  the time interval between
being case free and becoming a case.
= (140 − Age)0.81 ∗ ( )
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Data analysis
The abstracted data for the 800 patients initiated on
AZT-containing (n=400) and non-AZT containing
(n=400) ART regimens were exported to SPSS version
20.0 via Excel spread sheet and analyzed.
Qualitative data analysis techniques employed include
simple description like frequency and percentages.
Incidence was calculated as total cases of  AZT-induced
anaemia or worsening of anaemia during the study
period divided by person-time at risk and adjusted
per 100 person-years.  Normality tests were performed
for continuous variables using a one-sample
Kolmogorov Smirnov test. Statistical mean of
normally distributed variable was compared using two-
sample independent Student’s t-test and median of
non-normally distributed variables were compared
using Mann-Whitney U test across dichotomous
categorical variables. Average time-to-event and
survival curve were estimated using Kaplan-Meier
survival analysis. Inferential analyses were performed
at 95% confidence interval (CI) and a p-value <0.05
was considered to be statistically significant.
RESULTS
Study population
The 800 study participants were stratified into two
groups based on baseline anaemia status: Group A
consisted of patients with no baseline anaemia, and
Group B of those with baseline anaemia. Each group
was further divided into two sub-groups: those initiated
on non-AZT containing ART without and with
baseline anemia were sub-grouped as A1 and B1, and
those initiated on AZT-containing ART were sub-
grouped as A2 and B2, respectively. Within group A,
those that were initiated on non-AZT containing ART
regimens (subgroup A1) were younger, consisted of
more females, had higher CD4 cell counts, lower mean
haemoglobin concentrations, greater proportion
receiving cotrimoxazole prophylaxis, lower proportion
of participants with AIDS (immunological or clinical)
or advanced HIV infection (immunological or clinical),
fewer with weight less than 50 kg, and fewer with
renal impairment than those in subgroup A2, who
received AZT-containing ART regimen. Median
weight, median HIV viral load, hepatitis C infection,
hepatitis B virus (HBV) infection, incidence of
thrombocytopenia and neutropenia were comparable
between subgroups A1 and A2.
Among patients in group B, with baseline anaemia
participants in subgroup B2 were younger, had higher
mean haemoglobin concentrations, more received
cotrimoxazole prophylaxis, fewer had neutropenia and
were less likely to have AIDS (clinical), advanced HIV
infection (clinical), HBV coinfection, thrombo-
cytopenia, or renal impairment than subgroup B1.
Median weight, median viral load, proportion with
weight less than 50 kg, HCV coinfection, CD4 cell
counts, AIDS (immunological), advanced HIV
infection (immunological), female proportion and those
that were lost to follow-up  were comparable between
subgroup B1 (initiated on AZT -naïve regimen),  and
B2 (initiated on AZT). The baseline characteristics of
participants are presented in Table 1.
Group A
Patient without baseline anaemia
HB±SD = 12.101 ±1.1096
Group B
Patient with baseline anaemia















↕Gender: Female 70 (38.4) 148 (65.8) < 0.001 139 (62.3) 120 (68.6) 0.195
↕Weight ( < 50kg ) 28 (16.4) 29 (13.8) 0.485 84 (40.2) 56 (32.6) 0.124
CD4 Cell count <200 cells/ul
(Immunological AIDS)
116 (65.5) 126 (49.3) 0.001 156 (69.5) 110 (62.9) 0.163
↕Advanced HIV infection
(WHO stages III&IV)
176 (97.7) 210 (93.3) 0.040 218(98.2) 169 (96.6) 0.304
↕Cotrimoxazole use 58 (32.8) 150 (66.7) < 0.001 82 (36.8) 114 (65.1) < 0.001*
↕HCV infection 0 (0.0) 203 (0.9) 0.210 199 (0.9) 3 (1.7) 0.471
↕HBV infection 24 (13.6) 27 (12.9) 0.826 33 (14.9) 8 (4.6) 0.001*
↕Neutropenia 26 (14.7) 47 (21.1) 0.100 18 (8.1) 25 (14.5) 0.042*
↕Thrombocytopenia 30 (1.7) 61 (2.7) 0.513 13 (5.8) 2 (1.1) 0.015*
↕Renal impairment 33 (18.7) 15 (7.1) 0.001 100 (47.8) 49 (28.5) < 0.001*
↕Lost-to-follow 28 (15.8) 44 (19.6) 0.332 48 (21.5) 42 (24.0) 0.558
Table 1(a): Characteristics of  participants on AZT and non- AZT stratified by baseline anaemia
HB±SD = Mean haemoglobin concentration ± Standard deviation. *significant at p value < 0.05.
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Incidence of anemia by treatment group
Patients initiated on AZT-containing ART (Group A)
were 2.7 times more likely to develop anaemia than
those receiving non-AZT containing ART during the
first six month of  initiation (p = 0.005) (Table 2a).
Overall, the incidence of anaemia in patients initiated
on an AZT-containing regimen was 32.4% (60.5 per
100 person-years) which is 4.52 times the incidence of
anaemia among those receiving non-AZT containing
ART regimen (P< 0.001; 95% CI: 2.55, 8.01). Among
those with baseline anaemia (Group B), patients
receiving AZT were 2.17 times more likely to develop
worsening anaemia over baseline compared to those
on non-AZT-containing regimens in the first six month
of  ART  initiation (p = 0.013) (Table 2b). Overall, the
incidence of  worsening anaemia in AZT-containing
regimens was 30.5% (57.5 per 100 person-years) which
is significantly higher than the incidence of worsening
anaemia in the non-AZT cohort (p < 0.001; OR: 3.11;
95% CI: 1.87, 5.17).
Figure 2 shows changes in hemoglobin across 12-
months follow-up for both cohorts. Among patients
receiving AZT, despite commencing ART at
significantly higher haemoglobin concentrations (p =
< 0.001), produced comparable haemoglobin
concentration with non-AZT cohorts at end of the
study. While the AZT cohort (both subgroups A2 and
B2) curve produced several dips and was never
associated with a peak higher than its baseline
haemoglobin concentration, the non AZT was only
associated with one distinct dip in the early stage of
the study but characterized with several peaks above
baseline hemoglobin concentrations during the length
of  the study.
Group A
Patients without baseline anaemia
Group B
Patients with baseline anaemia
Non-AZT AZT Pvalue Non-AZT AZT P value
Age (years) median (IQR) 36 (28-42) 31 (26-38) 0.001* 34 (27-42) 32 (26-40) 0.177
Weight(kg) median (IQR) 60 (52-67) 59.25 (51.9-65.0) 0.403 52.5 (46.0-61.0) 53 (47.0-62.0) 0.176
CD4+ T lymphocyte
countmedian (IQR)
158 (102-248.5) 201    (117.0-
265.5)
0.031* 142 (66-242) 155 (59-244) 0.466









‡Hb Conc. (mean (SD)) 12.32 (1.3) 11.93 (0.8) 0.001* 8.41 (1.3) 9.16 (1.0) <0.001
Table 1(b): Mean ages and immunovirological parameters stratified by baseline anaemia.
*significant at p value < 0.05
X2-test employed to compare proportions
Mann-Whitney U employed to compare median
‡Independent student t-test employed to compare mean
Fig. 2: Changes in haemoglobin concentration between
the two regimen cohorts
Fig. 3: Survival analysis of  first occurrence of  anaemia
in patients without baseline anaemia by AZT treatment
group
Cumulative incidence of anemia
The cumulative incidence of anaemia over 12 months
for both  AZT and non-AZT cohorts without baseline
anaemia were 62.6% and 89.4% respectively (Figure
3). These survival curves were however significantly
different in both cohorts (p < 0.001). Subjects on non-
AZT regimens are significantly more likely to survive
without anaemia of all type at 12 months than those
with AZT-containing regimens.
Figure 3 shows that the 12-month cumulative survival
of worsening anaemia of all causes for AZT and non-
AZT in patients with baseline anaemia were 63.0%
and 86.4% respectively. These survival curves were






















P value OR 95% CI
0-6 63 (123) 1032 73.3 14 (50) 953.5 17.6 0.005* 2.70 1.33, 5.00
0-12 73 (225) 1448.5 60.5 17 (177) 1671.5 8.5 <0.001* 4.52 2.55, 8.01
Table 2(a): Incidence of  anaemia in patients initiating zidovudine (AZT) compared with non-AZT containing
regimens at selected time after initiation – Group A: patients without baseline anaemia






















P value OR 95% CI
0-6 43 (93) 782.5 65.9 25 (88) 1146.5 26.2 0.013* 2.17 1.17, 4.02
0-12 54 (177) 1127 57.5 28 (223) 1880.5 17.9 <0.001* 3.11 1.87, 5.17
Table 2(b): Incidence of  worsening anaemia in patients initiating zidovudine (AZT) compared with non-AZT
containing regimens at selected time after initiation – Group B: patients with baseline anaemia
*significant at p value < 0.05
WHO
Grades












1 9.5 - 10.5 12(30.00) 5.33 1 ( 2.04) 0.57 13 (3.25)
2 8 – 9.4 11(27.50) 4.89 20 (40.82) 11.43 31 (7.75)
3 6.5 - 7.9 10(25.00) 4.44 14 (28.57) 8.00 24 (6.00)
4 < 6.5 7 (17.50) 3.11 14 (28.57) 8.00 21 (5.25)
Total =< 10.5 40 (100) 17.78 49 (100) 28.00 89 (22.25)
Table 3: Grades of  first occurrence of  AZT- related anaemia
P value = 0.004, X2 test
Parameter Event description (first occurrence ) Total
Anaemia Worsening anaemia P value
Median time-to-event in
months (IQR))
2.25 (1.5, 3.38) 2.0 (1.5, 4.0) 0.750 2 (1.5, 3.75)
Average survival time in
months (95% CI)
10.3 (9.8, 10.8) 9.2 (8.6, 9.9) 0.012* 9.8 (9.42, 10.2)
*significant at p = 0.05
Table 4: Estimated time-to-event and survival time for AZT-related anaemia
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Table 3 shows the categorization of  the AZT-related
anaemia using WHO toxicity grading and their
respective incidence rate stratified by baseline anaemia
status. Incidence of  severe anaemia was 3.1% and 8.0%
for the groups without baseline anaemia and with
baseline anaemia, respectively. The group with baseline
anaemia was more likely to develop severe anaemia
(< 6.5 g/dl) (p = 0.004). Overall, the incidence of
severe anaemia in AZT-cohorts was 5.3%. It
contributed 23.6 % of  all grades of  anaemia  in AZT-
cohorts.
Time to new or worsening anemia
Among patients without baseline anemia, the median
time to first occurrence of anaemia was 2.3 months,
versus 2.0 months for the first occurrence of
worsening anaemia in the group with baseline anaemia,
respectively (Table 4). The median time-to-event was
however comparable in both groups whether
commencing AZT-containing ART with baseline
anaemia or not (p = 0.750). Overall, the median time-
to-event was 2.0 months. The estimated 1-year median
survival time was 10.3 months and 9.2 months for
first occurrence of anaemia in group without baseline
anaemia and for first worsening of anaemia in group
with baseline anaemia, respectively. The estimated
survival time was however longer in group without
baseline anaemia than in group with baseline anaemia
(p = 0.012). The overall estimated median survival
time was 9.8 months.
The proportional hazards regression adjusted for
confounding variables is as depicted in Table 5. The
multivariate analysis indicates; renal impairment (p =
0.005, HR: 2.117), HCV infection (p = 0.038, HR:
3.726), thrombocytopenia (p = 0.003, HR: 4.405),
concurrent cotrimoxazole use (p < 0.001, HR: 9.014)
and baseline haemoglobin (p = 0.003, HR: 0.982) as
independent predictors of  AZT- related anaemia in
patients on AZT-based HAART. While the renal
impairment, HCV infection, thrombocytopenia, and
concurrent cotrimoxazole use increase the incidence
of  AZT-related anaemia by 2.117, 3.726, 4.405 and
9.014 folds respectively, 1-g/dl increment in baseline
haemoglobin independently decrease AZT- related
anaemia by 2.8%.
Variable Group HR 95% CI for HR P value
CD4+ < 200 (immunological AIDS) No Reference
Yes NC NC .847
Baseline anaemia No Reference
Yes .477 0.212 – 1.073 .074
Renal impairment No Reference
Yes 2.117 1.253 – 3.576 .005*
HCV infection No Reference
Yes 3.726 1.076 – 12.907 .038*
Thrombocytopenia No Reference
Yes 4.405 1.644 – 11.801 .003*
Cotrimoxazole use No Reference
Yes 9.014 3.615 – 22.478 < 0.001*
AIDS (CD4+ < 200 or WHO Stage 4 or
both)
No Reference
Yes NC NC 0.852
Baseline Hb (1-g/dl increment) - 0.703 0.558 – 0.886 0.003*
Weight (1-kg increment) - 0.982 0.952 – 1.012 0.241
Table 5: Multivariate Analysis of  factors associated with AZT-related Anaemia
*significant at p value < 0.05, NC: not computed
Fig. 4: Survival analysis of  first worsening of  anaemia
in patients with baseline anaemia by AZT treatment
group
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DISCUSSION
Most data on HIV-related anaemia emanated from
developed countries. However, the consequences of
HIV-related anaemia is enormous and of  great concern
in resource-limited settings such as sub-Saharan
Africa.1,8,11-13 This current study evaluated the incidence
of  AZT-induced anemia among patients initiated on
ART. Patients without anaemia initiated on ART
including AZT were 2.7 times and 4.5 times likely to
develop anaemia than patients initiated on non-AZT
containing ART regimen when it was censored at 6
month and 12 month, respectively. The mean increase
in haemoglobin concentration was significantly higher
in cohorts initiated on non-AZT-containing ART
regimen despite initiation on therapy with lower mean
haemoglobin concentrations than those receiving AZT-
containing ART. Several earlier studies have
corroborated our findings of high incidence of
anaemia among HIV-infected patients initiated13,14 on
AZT-containing ART regimens. Anaemia is a common
feature of  HIV-related disease and has been shown to
independently predict morbidity and mortality
irrespective of CD4 cell count and HIV viral load.10,14
Although anaemia and other haematological
abnormalities associated with HIV infection often
respond to combination antiretroviral therapy,
zidovudine (AZT), a commonly used component of
antiretroviral therapy in resource-limited settings, is
associated with myelotoxicity that often manifest as
anaemia.13,14 The AZT is associated with risk of
myelosuppression that often manifest as anaemia than
neutropenia and thrombocytopenia. It therefore
increases the incidence of anaemia in patients on AZT
oriented ART.8,10,11,14
The estimated median time to development of new
or worsening AZT-related anaemia in this 12-month
follow-up study, regardless of  baseline anaemia, was
2.0 months (IQR: 1.5, 3.8). Further, when stratified by
baseline anaemia status, the median time-to-event was
comparable between the group with baseline anaemia
and that without baseline anaemia.  This median time-
to-event was comparable to the findings of Ssali et al.8
in Uganda; Curkendall et al.14 in United States of
America (USA); Katjitae et al. 15 in Namibia and Daka,
Lelissa and Amsalu in Southern Ethiopia12 and as well
as a multi-center study from sub-Saharan Africa, Asia
–Pacific and central and Southern America by Zhou et
al.16 The studies identified AZT-related anaemia as an
early toxicity occurring mostly within the first six
months. The finding of  early AZT related toxicity is in
agreement with the WHO recommendation on strict
and close interval monitoring for anaemia in the first
three months of  AZT-containing ART.17 However,
despite WHO recommended guideline for monitoring
of  AZT-related haematological toxicity, reports from
developing countries indicates poor adherence to the
WHO recommended guidelines.18,19 This lack of
appropriate monitoring for early findings of reversible
AZT-related anaemia may complicate treatment and
worsen prognoses and subsequently undermine HIV
intervention programs.18-20
The overall incidence of 22.3% (38.2 per 100 patient-
years) obtained in our study was higher than previous
studies despite using a lower cut-off value to define
anaemia (haemoglobin <10.5 gm/dl), irrespective of
gender. It was however similar to findings by Moh et
al.20 in Ivory Coast. Study design, cut off value for
defining anaemia, and geographical location may all
influence the anaemia incidence results.
In this report when AZT-related anaemia was censored
at 6 months and further categorized using WHO
toxicity grading, severe anaemia (haemoglobin < 6 g/
dl) was reported in 5.3% irrespective of baseline
anaemia and was significantly higher in patients with
baseline anaemia. This finding is consistent with WHO
estimates for adults and adolescents17,21 and previous
reports22-24 which report an incidence of  severe AZT-
related anaemia in low and medium income countries
of around 7%. Severe anaemia has been associated
with poorer prognosis as it increases morbidity and
mortality in HIV-infected patients.25,26
On multivariate analysis, HCV sero-positivity, renal
impairment (ClCr <60ml/min) and concomitant
cotrimoxazole were significantly associated with risk
of  AZT-related anaemia. AZT is metabolized by
glucuronidation and its major metabolite is excreted
through the renal system, thus in patients with renal
impairment, failure to clear AZT may result in systemic
accumulation of the drug, predisposing patients to
AZT-related toxicity.17,25
Baseline Haemoglobin concentration correlated
negatively with occurrence of  AZT-related anaemia
in the multivariate analysis, meaning that for every 1-
g/dl increase in baseline haemoglobin the hazard for
AZT-related anaemia was decreased by 29.7%. This
finding is consistent with that of Curkendall et al.14,
who found 50.1% decreases in anaemia incidence for
every 1-g/dl mean increase in baseline Haemoglobin,
Katjitae et al.,15 who found 12% increase in severe
anaemia with every 1-g/dl decrease in baseline
Haemoglobin. Both the WHO evidence based risk
management consideration for prescription of AZT
in the management of  HIV infecion17 and DART trial
in Uganda8 also identified significant correlation
between baseline haemoglobin and subsequent risk of
AZT-related anaemia.
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Concomitant cotrimoxazole use was identified as a
correlate by multivariate analysis for AZT- related
anaemia, which implies that patients who had
cotrimoxazole concomitantly with AZT-based ART
are at risk of anaemia than those AZT cohorts without
cotrimoxazole use. This observation is not consistent
with report by Curkendall et al.17 whose univariate
proportional hazards analysis show association but
failed significant test when it was adjusted for
confounding variables in multivariate proportional
hazards regression analysis. Randomized control trial
in Uganda and Zimbabwe by Ssali et al.8 also failed to
demonstrate any correlation between anaemia incidence
in ART and cotrimoxazole use. This association of
cotrimoxazole use with AZT-related anaemia may be
explained by the fact that cotrimoxazole, apart from
its myelosppressive effect, has been reported to also
contribute to zidovudine-induced anaemia by reducing
the clearance of zidovudine through the kidney with
resultant increase in the plasma level and subsequent
toxicity.27
CONCLUSION
HIV-infected patients initiated on AZT-containing ART
are 2.7 and 4.5 more likely to develop anaemia at 6
and 12 months respectively, than patients initiated on
non-AZT containing regimens. When censored at 12
months the overall incidence of  AZT-related anaemia
was estimated to be 22.3% (38.2 per 100 person-years).
The majority (75%) of  AZT-related anaemia occurred
early with estimated time-to-event occurring within the
first 3.8 months (range, 0-15 weeks).
Recommendations
We recommend strict adherence of  WHO guidelines
of regular haemoglobin monitoring in patients initiating
AZT-containing ART at week 4, 8, 14, and 24 to
identify AZT-related anaemia as early as possible to
avoid complication since it is an early medication
toxicity.
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